Pharmaceutical News

RSS

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

Cangene Corporation today reports that it has received a positive opinion from the EMA's Committee for Medicinal Products for Human Use ("CHMP") regarding the immunoprophylaxis indication of Cangene's ImmunoGam(TM) (Human Hepatitis B Immunoglobulin).

18 Dec 2009

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

Nu Skin Enterprises launches the new ageLOC Future Serum

Nu Skin Enterprises, Inc. introduced the new ageLOC Future Serum to more than 10,000 sales representatives at its launch event in Japan. Japanese distributors were eager to be in the first market to fully launch one of the company's new ageLOC skin care products that targets the sources of aging by resetting youth gene clusters to a more youthful pattern. The ageLOC products are marketed as 'genLOC' in Japan.

18 Dec 2009

Jubilant Organosys announces new facility for Niacinamide and 3-Cyanopyridine

Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, announced today that it is setting up Niacinamide and 3-Cyanopyridine plant of 10,000 TPA each, expected to be ready by end of 2010.

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.

18 Dec 2009

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom.

18 Dec 2009

Nutricia North America improves its packaging with BPA-free lining for all powdered products

Nutricia North America, a manufacturer of medical foods and specialized infant formulas such as Neocate®, announced today that it has begun packaging its powdered medical foods and specialized infant formulas in cans with BPA-free lining.

18 Dec 2009

Proprietary adult stem cell platform, an effective treatment for diabetes, shows study

Australia's regenerative medicine company, Mesoblast Limited, today announced significant preclinical trial results showing that the proprietary adult stem cell platform could be an effective treatment for diabetes.

18 Dec 2009

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.

18 Dec 2009

ISTA Pharmaceuticals files sNDA for bromfenac ophthalmic solution

ISTA Pharmaceuticals, Inc., today announced the Company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for bromfenac ophthalmic solution dosed once-daily as a treatment for ocular inflammation and pain following cataract surgery.

18 Dec 2009

Treprostinil drug reduces breathlessness in PAH patients, says study

Patients with a rare, deadly disease that mostly affects young women felt a dramatic reduction in breathlessness using an approved drug, according to study results published online today in The Journal of Heart and Lung Transplantation.

18 Dec 2009

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.

18 Dec 2009

BDI Pharma introduces SecuriVAX for online ordering of vaccines

BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced today the introduction of SecuriVAX(SM) (www.securivax.com), an online supply solution providing the healthcare community a one-stop source for a wide variety of vaccines.

18 Dec 2009

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1.

18 Dec 2009

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Unigene Laboratories, Inc. (http://www.unigene.com) announced today that it has selected a lead peptide compound, designated UGP281, from its obesity program for development.

18 Dec 2009

Antidepressants may play a key role in improving adolescents’ mental health

Suicidal adolescents who were prescribed an antidepressant medication during inpatient psychiatric hospital treatment were 85 percent less likely than others to be readmitted within a month after discharge, a new study found.

18 Dec 2009

Duane Reade offers H1N1 immunization vaccines for New York residents

Duane Reade, the largest drug store chain in New York City, today announced plans for its H1N1 immunization program as part of the Company's commitment to meet the health and wellness needs of New Yorkers and to be a destination for their flu related needs.

18 Dec 2009

Pharmaceutical News

GSK receives European CHMP positive opinion for Revolade

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

Nu Skin Enterprises launches the new ageLOC Future Serum

Jubilant Organosys announces new facility for Niacinamide and 3-Cyanopyridine

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Nutricia North America improves its packaging with BPA-free lining for all powdered products

Proprietary adult stem cell platform, an effective treatment for diabetes, shows study

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

ISTA Pharmaceuticals files sNDA for bromfenac ophthalmic solution

Treprostinil drug reduces breathlessness in PAH patients, says study

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

BDI Pharma introduces SecuriVAX for online ordering of vaccines

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Antidepressants may play a key role in improving adolescents’ mental health

Duane Reade offers H1N1 immunization vaccines for New York residents

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News